HCW Biologics is a biopharmaceutical company focused on discovering and developing immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. Co. has selected two molecules as its primary product candidates: HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the Senescence-Associated Secretory Phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9302 is designed to activate and expand regulatory T cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete. We show 7 historical shares outstanding datapoints in our coverage of HCWB's shares outstanding history.
Understanding the changing numbers of HCWB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like HCWB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching HCWB by allowing them to research HCWB shares outstanding history
as well as any other stock in our coverage universe. |
Free HCWB Email Alerts:
Video: Shares Outstanding Importance
